Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for Gadobutrol Injection (7.5ml:4.5354g) from National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Gadobutrol Injection is mainly used for diagnostic purposes and is for intravenous administration only. It is for adults and children of all ages (including full-term newborns). It is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord), as well as contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body.

As stated in the Company's announcement dated 21 July 2026, the Group's Gadobutrol bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. As a new generation of magnetic resonance imaging contrast agent with macrocyclic structure, Gadobutrol further enriches the Group's product portfolio of diagnostic treatment drugs. Gadolinium is a rare-earth metal, and this approval of injection completes the integrated business layout of bulk drugs and injection preparations under Gadolinium category, which helps expand the clinical market for medical imaging and creates business synergies with the Group's existing formulations.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Indocyanine Green for Injection (25mg) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Indocyanine Green for Injection is mainly used to diagnose various liver diseases such as cirrhosis, liver fibrosis, chronic hepatitis, occupational and drug-induced liver diseases, and to understand the extent of damage and reserve function of liver. It can also be used for choroidal angiography to determine the location of choroidal diseases.

As stated in the Company's announcement dated 9 September 2025, the Group's Indocyanine Green bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This approval of powder form for injection further improves the product portfolio for perioperative and ICU department. Leveraging the advantage of integration of bulk drugs and preparations, it helps expand the surgical and critical care market in 3A hospitals, and creates synergies with existing preparations for critical care.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 27 August 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.